HALUK YUZUGULLU
HALUK YUZUGULLU
Astrazeneca Pharmaceuticals
Verifierad e-postadress på astrazeneca.com
Titel
Citeras av
Citeras av
År
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
HYJJZ Lauren M. Thorpe
Nature Reviews Cancer 15 (1), 7–24, 2014
831*2014
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
JJZ Shom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon ...
Cancer Cell 29 (3), p255–269, 2016
2402016
CDK7-dependent transcriptional addiction in triple-negative breast cancer
Y Wang, T Zhang, N Kwiatkowski, BJ Abraham, TI Lee, S Xie, H Yuzugullu, ...
Cell 163 (1), 174-186, 2015
2362015
Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells
H Yuzugullu, K Benhaj, N Ozturk, S Senturk, E Celik, A Toylu, N Tasdemir, ...
Molecular cancer 8 (1), 1-20, 2009
2272009
Senescence and immortality in hepatocellular carcinoma
M Ozturk, A Arslan-Ergul, S Bagislar, S Senturk, H Yuzugullu
Cancer letters 286 (1), 103-113, 2009
932009
Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation
O Gursoy‐Yuzugullu, H Yuzugullu, M Yilmaz, M Ozturk
Liver International 31 (4), 561-571, 2011
672011
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
SP Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE ...
Cancer Cell 31 (4), 576–590, 2017
592017
Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
K Gritsman, H Yuzugullu, T Von, H Yan, L Clayton, C Fritsch, SM Maira, ...
The Journal of clinical investigation 124 (4), 1794-1809, 2014
512014
Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis
G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu, ...
PloS one 8 (5), e64016, 2013
472013
A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis
H Yuzugullu, L Baitsch, T Von, A Steiner, H Tong, J Ni, LK Clayton, ...
Nature communications 6 (1), 1-13, 2015
332015
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity
M Mumcuoglu, S Bagislar, H Yuzugullu, H Alotaibi, S Senturk, ...
PloS one 5 (6), e11288, 2010
222010
NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways
H Yuzugullu, T Von, LM Thorpe, SR Walker, TM Roberts, DA Frank, ...
Cell discovery 2 (1), 1-13, 2016
132016
Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer
S Ghassemifar, Y Hashambhoy-Ramsay, H Yuzugullu, T Utermark, ...
Cancer Research 79 (13), 2019
2019
Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
D Tamara, S Ghassemifar, Y Hashambhoy-ramsay, DHC MARCANTONIO, ...
US Patent App. 16/305,289, 2019
2019
INVESTIGATION OF CAUSATIVE AGENTS IN COMMUNITY-ACQUIRED ATYPICAL PNEUMONIA CASES
E ÇALIŞKAN, Ş ÖKSÜZ, C ÖZTÜRK, I Sahin, O Kilincel, N Akar, ...
2019
MM-161, a first-in-class pan-FGFR antibody
T Dake, G Finn, M Geddie, N Kohli, M Razlog, L Xu, V Paragas, ...
Cancer Research 77 (13 Supplement), 22-22, 2017
2017
Targeted Therapy for Hepatocellular Carcinoma: What`s New?
H Yuzugullu, O Gursoy-Yuzugullu
Liver Res Open J 1 (1), e1-e3, 2015
2015
PI3K-p110β is required for leukemic transformation and HSC depletion in the absence of Pten
H Yuzugullu, L Baitsch, A Steiner, LK Clayton, K Gritsman, JJ Zhao
Cancer Research 74 (19 Supplement), 4775-4775, 2014
2014
Genome-Wide Transcriptional Reorganization Associated with Senescence-to
G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu
2013
Doxorubicin-induced senescence in hepatocellular carcinoma cells
O Gursoy-Yuzugullu, H Yuzugullu, M Ozturk
Cancer Research 70 (8 Supplement), 3220-3220, 2010
2010
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20